Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
10 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04381650 | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 161 | TakedaINDUSTRY | 9 | Dec 10, 2025 | clinicaltrials |
| NCT03059823 | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | completed | Phase 1 | 325 | Incyte CorporationINDUSTRY | 16 | Aug 3, 2025 | clinicaltrials |
| Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer |
| completed |
| Phase 1 |
| 15 |
| Ganymed Pharmaceuticals GmbHINDUSTRY |
| 2 |
| Nov 21, 2024 |
| clinicaltrials |
| NCT01671774 | Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer(PILOT) | completed | Phase 1 | 29 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 14, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT01784757 | Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer(ARAFOR) | completed | Phase 1 | 30 | Orion Corporation, Orion PharmaINDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT02344017 | Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer(DUALIDES) | completed | Phase 1 / Phase 2 | 23 | Orion Corporation, Orion PharmaINDUSTRY | 4 | Dec 19, 2019 | clinicaltrials |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects | completed | Phase 1 | 186 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Oct 22, 2013 | clinicaltrials |
| NCT00785122 | IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)(IMA910-101) | completed | Phase 1 / Phase 2 | 92 | Immatics Biotechnologies GmbHINDUSTRY | 9 | May 16, 2013 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials